Table 5.

Prospective Trials of IMiDS or Proteasome Inhibitors in Allografting

Ref	Intervention, n	NRM/RR	PFS/OS	Comment
[56]	DLI only: 6 DLI + IMiD and/or bortezomib: 24	0%/NS	CR pts: 58%/90% at 5 yr No CR pt 35%/62% at 5 yr	59% CR by EBMT criteria; CR improved survival; 33% grade II–IV GVHD
[57]	Lenalidomide	6%/42%	52%/79% at 3 yr	28% grades II–IV aGVHD
[58]	Lenalidomide 30	10%/27%	63%/78% at 18 mo	30% aGVHD grades II–IV; 47% of all planned cycles completed; most common dose upon completing study 5 mg QOD
[59]	Lenalidomide	NS/NS	61%/94% at 2 yr	37% aGVHD II–IV; 11% chronic extensive GVHD; only 10% of patients completed planned therapy
[60]	Bortezomib	25%/54%	30%/41% @ 3 yr	25% grade III aGVHD
[61]	Bortezomib as part of conditioning	16.9%/NS	74%/77% at 2 yr	No post-transplantation maintenance in most patients

DLI indicates donor lymphocyte infusion; aGVHD, acute graft-versus-host disease; QOD, every other day.